Division of Infectious Diseases, Henry Ford Hospital, Detroit, Michigan, USA.
Curr Opin Infect Dis. 2023 Oct 1;36(5):353-359. doi: 10.1097/QCO.0000000000000958. Epub 2023 Aug 17.
The human gut harbors a diverse community of microorganisms known as the gut microbiota. Extensive research in recent years has shed light on the profound influence of the gut microbiome on human health and disease. This review aims to explore the role of the gut microbiome in various clinical conditions and highlight the emerging therapeutic potential of targeting the gut microbiota for disease management.
Knowledge of the influence of gut microbiota on human physiology led to the development of various therapeutic possibilities such as fecal microbiota transplant (FMT), phage therapy, prebiotics, and probiotics. Recently, the U.S. FDA approved two FMT products for the treatment of recurrent Clostridioides difficile infection with ongoing research for the treatment of various disease conditions.
Advancement in the knowledge of the association between gut microbiota and various disease processes has paved the way for novel therapeutics.
人类肠道中栖息着种类繁多的微生物群落，被称为肠道微生物群。近年来的广泛研究揭示了肠道微生物组对人类健康和疾病的深远影响。本综述旨在探讨肠道微生物群在各种临床病症中的作用，并强调针对肠道微生物群进行疾病管理的新兴治疗潜力。
对肠道微生物群对人体生理学影响的认识，催生了各种治疗可能性，如粪便微生物群移植（FMT）、噬菌体治疗、益生元和益生菌。最近，美国食品和药物管理局（FDA）批准了两种 FMT 产品用于治疗复发性艰难梭菌感染，同时也在进行各种疾病治疗的研究。
对肠道微生物群与各种疾病过程之间关联的认识的提高为新的治疗方法铺平了道路。
